Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Nuwellis, Inc. (Nasdaq: NUWE), a medical technology and medical device company focused on precision fluid management for patients with cardio-renal conditions and fluid overload. Through these filings, investors can review how Nuwellis reports its financial performance, material events, and key developments related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Current report filings (Form 8-K) for Nuwellis often cover topics such as quarterly financial results, changes in executive roles, new patents, NIH grant-supported programs, FDA 510(k) clearances for accessories like catheters, and at-the-market equity offering agreements. Some 8-K filings also reference press releases announcing clinical registry findings, such as the ULTRA-Peds pediatric Aquadex registry, or new intellectual property supporting pediatric safety features and hemolysis sensing in extracorporeal circuits.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed discussions of Nuwellis’ business, including its focus on fluid overload, its Aquadex SmartFlow system, development-stage technologies like Vivian, and its geographic footprint with headquarters in Minneapolis and a subsidiary in Ireland. These filings also describe risk factors, liquidity, capital-raising activities, and other information relevant to NUWE shareholders.
Stock Titan’s platform enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings, highlight important changes from prior periods, and help users quickly understand complex disclosures. Investors can also use this page to follow real-time updates as new Nuwellis filings are posted to EDGAR, including current reports, registration statements, and other material submissions related to NUWE.
Nuwellis, Inc. is asking stockholders to vote at its 2026 annual meeting, to be held virtually on April 28, 2026 at 2:00 p.m. U.S. Central Time. Holders of common stock at the March 24, 2026 record date, when 2,635,718 shares were outstanding, may participate and vote.
Stockholders are being asked to elect two Class I directors, Martin Emerson and David McDonald, to terms running to the 2029 meeting, and to approve on an advisory basis the appointment of Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR the auditor ratification.
Nuwellis, Inc. filed an amended current report to update an earlier disclosure about board resignations. This Amendment No. 1 adds as exhibits supplemental response letters from former directors Katharyn Field and Mika Grasso addressing the company’s initial description of their March 26, 2026 resignations.
The company states it does not agree with certain statements in these response letters and maintains that its original account in the initial filing is accurate. Nuwellis emphasizes that the resignation and response letters reflect only the former directors’ personal views and may conflict with management’s and the board’s views.
The company cautions that it does not take responsibility for the contents of the former directors’ letters and encourages stockholders and investors to rely on information in its official SEC reports, including its most recent annual and quarterly reports.
Nuwellis, Inc. director Emerson Martin J filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a director and provides a baseline disclosure of his equity relationship with the company. The report does not list any specific transactions or holdings in the provided data.
Nuwellis, Inc. has completed its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology. This technology is designed to support clinical decision-making for critically ill patients, potentially broadening Nuwellis’ clinical offerings in advanced patient monitoring.
Nuwellis, Inc. files its annual report describing a small medical-device company focused on the Aquadex ultrafiltration system for cardiorenal fluid management. The business is concentrated in pediatrics, critical care and heart failure, with U.S. growth prioritized and most international operations exited.
The company discloses that existing cash only funds operations through the second quarter of 2026 and that additional capital is needed to operate through year-end 2026, raising substantial doubt about its ability to continue as a going concern. Nuwellis is outsourcing manufacturing to KDI Precision, investing in software upgrades and an NIH‑backed pediatric CRRT device, but also reports material weaknesses in internal controls.
Nuwellis, Inc. reported mixed fourth quarter and full year 2025 results. Q4 2025 revenue was $2.4 million, up 4% year over year and 9% sequentially, driven by stronger U.S. console sales and higher circuit pricing. Q4 gross margin improved to 68.2% from 58.4%, while operating loss was about $2.4 million, roughly flat with the prior-year quarter.
For full year 2025, revenue was $8.3 million, down 5% from 2024, with Heart Failure and Pediatrics growth offset by weaker Critical Care. Gross margin for the year was 62.0%. Net loss attributable to common shareholders was $17.5 million, including a $6.4 million non-cash warrant valuation expense and about $0.3 million of executive severance. As of December 31, 2025, Nuwellis had $1.2 million in cash, cash equivalents and restricted cash and no debt, after using $10.8 million of cash in operating activities and raising $6.9 million through equity financings during the year.
Nuwellis, Inc. director David McDonald reported his holdings of nonstatutory stock options in a Form 3. Following the reported positions, one option grant covers 7 underlying shares and another covers 416 underlying shares, both held directly. One option is fully vested and another vests in 12 approximately equal monthly installments.